- Home
- ZNTL vs TARA Comparison
ZNTL vs TARA Comparison
Compare ZNTL & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZNTL
- TARA
- Stock Information
- Founded
- ZNTL 2014
- TARA N/A
- Country
- ZNTL United States
- TARA United States
- Employees
- ZNTL N/A
- TARA N/A
- Industry
- ZNTL Biotechnology: Pharmaceutical Preparations
- TARA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ZNTL Health Care
- TARA Health Care
- Exchange
- ZNTL Nasdaq
- TARA Nasdaq
- Market Cap
- ZNTL 102.2M
- TARA 120.8M
- IPO Year
- ZNTL 2020
- TARA N/A
- Fundamental
- Price
- ZNTL $1.28
- TARA $3.31
- Analyst Decision
- ZNTL Buy
- TARA Strong Buy
- Analyst Count
- ZNTL 9
- TARA 7
- Target Price
- ZNTL $8.69
- TARA $20.67
- AVG Volume (30 Days)
- ZNTL 687.2K
- TARA 292.4K
- Earning Date
- ZNTL 05-14-2025
- TARA 05-08-2025
- Dividend Yield
- ZNTL N/A
- TARA N/A
- EPS Growth
- ZNTL N/A
- TARA N/A
- EPS
- ZNTL N/A
- TARA N/A
- Revenue
- ZNTL $26,865,000.00
- TARA N/A
- Revenue This Year
- ZNTL N/A
- TARA N/A
- Revenue Next Year
- ZNTL N/A
- TARA N/A
- P/E Ratio
- ZNTL N/A
- TARA N/A
- Revenue Growth
- ZNTL N/A
- TARA N/A
- 52 Week Low
- ZNTL $1.01
- TARA $1.60
- 52 Week High
- ZNTL $12.68
- TARA $10.48
- Technical
- Relative Strength Index (RSI)
- ZNTL 41.45
- TARA 41.40
- Support Level
- ZNTL $1.18
- TARA $3.02
- Resistance Level
- ZNTL $1.27
- TARA $3.34
- Average True Range (ATR)
- ZNTL 0.07
- TARA 0.17
- MACD
- ZNTL 0.01
- TARA 0.01
- Stochastic Oscillator
- ZNTL 26.67
- TARA 25.44
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).